Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522777

Opioid Toxicity: An Interdisciplinary Approach to Clinical Management, Nursing Care, and Health Security-An Updated Review.

Kamilah Mohammad Shagiri[(1)], Fatimah Yousef Ali Qawfashi[(2)], Afnan Owaynan khalaf ALJAMEELI[(3)], Atlal Fraih Alanazi[(4)], Majed Mubarak Saeed Alshahrani[(5)], Akram Ali Ahmed Rayyani[(6)], Amal Fahad Othman Alsenani[(7)], Sabhb Abdo Mohammed Bakr[(8)], Majed ObaIdallah Matter Alharbi[(9)], HAMZAH MOHAMMED AHMED BUAYTI[(10)], ASMA MOHAMMED JABER SULAYYI[(11)], YASMEEN MUBARAK SAYED AL-DAFERI[(12)]

(1)Riyadh Primary Health Center, Ministry of health, Saudi Arabia
(2)Al Hurath General Hospital, Jazan Health Cluster, Ministry of health, Saudi Arabia
(3)Maternity and Children Hospital, Hafar Al-Batin, Health Holding Company, Ministry of health, Saudi Arabia
(4)Alrumhiya Primary Healthcare Center, Ministry of Health, Saudi Arabia
(5)King Khalid Hospital, Al-Kharj, Ministry of Health, Saudi Arabia
(6)Irada and Mental Health Hospital, Jazan, Ministry of Health, Saudi Arabia
(7)Riyadh Second Health Cluster, School Health, Health Holding Company, Ministry of health, Saudi Arabia
(8)Tuwaiq General Center, First Health Cluster, Ministry o health, Saudi Arabia
(9)Ghamrah Primary Health Center, Sumaira Hospital, Ministry of Health, Saudi Arabia
(10)Eradah and Mental Health Hospital, Jazan, Ministry of health, Saudi Arabia
(11)Abu Arish General Hospital, Jazan, Ministry of health , Saudi Arabia
(12)King Khalid General Hospital, Hafr Al-Batin, Ministry of health , Saudi Arabia

Abstract

Background: Opioid toxicity represents a major clinical and public health concern associated with respiratory depression, impaired consciousness, overdose, dependence, and death. Although opioids remain important medications for acute and chronic pain, inappropriate use, high-dose exposure, drug interactions, and substance-use disorders increase the risk of serious adverse outcomes. Nurses and health security professionals have important roles in early recognition, emergency management, monitoring, prevention, education, and coordination of care.

Aim: This review aimed to examine the causes, risk factors, clinical assessment, evaluation, medical management, nursing management, monitoring, health education, risk management, and discharge planning associated with opioid toxicity.

Methods: A narrative review approach was used to synthesize available clinical and professional literature addressing opioid pharmacology, toxicity, overdose risk, diagnostic assessment, opioid reversal, nursing interventions, medication monitoring, multidisciplinary coordination, and preventive strategies.

Results: Opioid toxicity was characterized primarily by central nervous system depression and respiratory impairment. Major risk factors included high opioid exposure, substance-use history, concurrent use of central nervous system depressants, opioid-naivety, and sleep apnea. Early recognition of hypoventilation and airway compromise was central to management. Supportive airway and ventilation measures and naloxone administration were key components of emergency care. Long-term management incorporated patient education, monitoring, pharmacotherapy for opioid use disorder, prescription surveillance, pharmacist involvement, and structured discharge planning.

Conclusion: Effective opioid toxicity management requires coordinated clinical assessment, rapid respiratory support, appropriate opioid reversal, continuous monitoring, patient education, and long-term risk reduction.

Keywords: Opioid toxicity, opioid overdose, opioid use disorder, naloxone, nursing management, respiratory depression, overdose prevention, health security.

Introduction

Opioids and opiates constitute a broad class of analgesic agents that have an established role in the management of pain, particularly when pain intensity is substantial or when other analgesic strategies provide inadequate relief. Pharmacological management of acute pain is generally guided by pain severity, underlying pathology, expected duration, and the patient's clinical characteristics. For mild to moderate acute pain, non-opioid analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used as initial treatment options because they can provide effective analgesia without exposing patients to the respiratory and central nervous system effects associated with opioid therapy. When these agents do not provide sufficient pain control, multimodal approaches may be considered, including combinations of non-opioid

*Corresponding author e-mail: mmkzo00020@gmail.com (Kamilah Mohammad Shagiri).
Receive Date: 07 December 2025, Revise Date: 29 December 2025, Accept Date: 31 December 2025

analgesics with opioid medications. Potent opioids remain important therapeutic agents for severe acute pain, particularly when rapid and substantial analgesia is required. However, their clinical benefits must be balanced against the risks of sedation, respiratory depression, tolerance, dependence, misuse, and overdose.[1] These considerations require healthcare professionals, particularly nurses and emergency healthcare personnel, to maintain a clear understanding of opioid pharmacology, appropriate administration, early recognition of toxicity, and timely intervention. The terminology used to describe these substances reflects differences in their origin and chemical characteristics. Traditionally, the term opiates has been used to describe naturally occurring compounds derived from the opium poppy, whereas opioids represents a broader category that includes naturally derived substances, semisynthetic compounds, and fully synthetic agents that exert their effects through opioid receptors. Despite their therapeutic value, both opioid and opiate compounds have considerable potential for misuse and dependence. Their widespread availability for medical purposes, combined with their effects on reward pathways and central nervous system function, has contributed to their role in substance misuse and opioid-related morbidity and mortality. Opioid misuse has therefore developed into a major public health concern, with particularly substantial consequences in developed countries and notably in the United States since the early 2000s.[2][3] The clinical significance of this problem extends beyond substance-use treatment because opioid-related toxicity can present in emergency departments, inpatient units, community settings, and prehospital environments. Nurses and health security professionals therefore have important responsibilities in identifying individuals at risk, recognizing manifestations of opioid toxicity, implementing appropriate emergency measures, and supporting systems designed to reduce preventable harm.

The burden associated with opioid misuse is substantial among individuals receiving these medications for chronic pain. Approximately 21% to 29% of patients prescribed opioids for chronic pain have been reported to misuse them, while approximately 8% to 12% may develop an opioid use disorder. Among individuals who misuse prescription opioids, an estimated 4% to 6% subsequently transition to heroin use, demonstrating the potential relationship between prescription opioid exposure, problematic use, and progression to other forms of opioid dependence.[4] These patterns create challenges for clinicians because opioids remain necessary for selected patients while inappropriate exposure and misuse can produce serious individual and population-level consequences. Healthcare systems must therefore balance adequate pain management with responsible prescribing, patient assessment, monitoring, education, and early identification of problematic opioid use. Opioid toxicity represents one of the most clinically significant consequences of excessive opioid exposure. Respiratory depression is a central feature of severe opioid poisoning and can progress to hypoxemia, loss of consciousness, cardiac arrest, and death when treatment is delayed. The scale of opioid-related mortality illustrates the importance of early recognition and coordinated intervention. In 2016, opioid overdoses were associated with more than 42,000 deaths in the United States, representing the highest annual number recorded at that time, and approximately 40% of opioid overdose deaths involved a prescription opioid.[4] These figures demonstrate that opioid toxicity is not restricted to illicit drug exposure and may occur following therapeutic prescribing, medication misuse, accidental ingestion, or exposure to potent synthetic opioids. Effective management therefore requires an integrated approach involving clinical assessment, continuous monitoring, airway and respiratory support, appropriate use of opioid antagonists such as naloxone, post-intervention observation, and referral for further assessment when indicated. From a nursing and health security perspective, addressing opioid toxicity also requires preparedness across healthcare settings, consistent emergency protocols, appropriate staff education, surveillance of opioid-related events, and coordinated strategies aimed at reducing preventable overdose and improving patient safety.



Figure 1: Opioid Toxicity.

Nursing Diagnosis

Nursing diagnosis in opioid toxicity should be based on the patient's respiratory status, level of consciousness, airway protection, cardiovascular stability, functional capacity, and psychological response. Because opioid toxicity can produce central nervous system depression with reduced respiratory drive, impaired oxygenation, and diminished protective airway reflexes, respiratory problems generally represent the immediate clinical priority. Impaired gas exchange may occur as a consequence of opioid-induced hypoventilation, in which reduced respiratory rate and tidal volume impair alveolar ventilation and compromise oxygen and carbon dioxide exchange. The nurse should assess respiratory rate, depth and pattern, oxygen saturation, skin and

mucosal color, level of consciousness, and other indicators of respiratory deterioration. Ineffective breathing pattern is another important nursing diagnosis when opioid exposure produces slow, shallow, irregular, or otherwise inadequate ventilation. Close respiratory observation is essential because deterioration may occur while the patient remains minimally responsive or unable to communicate symptoms. Ineffective airway clearance may also develop because central nervous system depression can reduce the patient's ability to cough effectively and maintain airway patency. Accumulation of secretions, reduced muscle tone, and diminished protective reflexes can further compromise ventilation. Impairment in breathing therefore requires prompt assessment and continuous reassessment, particularly when respiratory depression accompanies reduced consciousness. Risk for aspiration should also be considered because opioid-induced sedation, vomiting, impaired swallowing, and loss of protective airway reflexes can allow gastric contents or secretions to enter the respiratory tract. Nursing assessment should therefore include the patient's ability to maintain airway protection and respond appropriately to stimulation [1][2][3]. Activity intolerance may result from hypoxemia, sedation, reduced physiological reserve, or impaired neuromuscular function. The patient's ability to perform routine activities should be evaluated according to clinical stability and level of consciousness. Anxiety may occur in patients experiencing respiratory distress, altered consciousness, fear, or uncertainty regarding their condition. Its severity may range from mild or moderate anxiety to severe anxiety or panic. Nurses should assess behavioral and physiological manifestations while maintaining a calm and structured environment. Overall, nursing diagnoses should be individualized according to the patient's presenting findings, with immediate attention directed toward ventilation, airway protection, oxygenation, and prevention of aspiration before addressing functional and psychological needs [3].

Causes

Opioid toxicity can result from exposure to opioid or opiate compounds at doses that exceed an individual's capacity to tolerate their pharmacological effects. These substances include naturally occurring opiates derived from the opium poppy, semisynthetic derivatives produced through chemical modification of naturally occurring compounds, and synthetic opioids produced through chemical synthesis. Although these agents differ in their chemical structures and pharmacokinetic properties, they exert their principal effects through interaction with opioid receptors within the central and peripheral nervous systems. The clinical consequences of opioid exposure depend on the specific agent, dose, route of administration, duration of exposure, patient characteristics, and presence of other substances or medications. Opioid-related toxicity may therefore occur after therapeutic administration, excessive dosing, medication errors, intentional misuse, recreational exposure, or interactions with other central nervous system depressants. The principal opioid receptor systems include mu, kappa, and delta receptors, together with other receptor systems such as nociceptin and zeta receptors. Mu-opioid receptor activation accounts for many of the characteristic therapeutic and toxic effects of opioids. These effects include analgesia, respiratory depression, bradycardia, physical dependence, gastrointestinal dysmotility, and euphoria. Excessive stimulation of mu receptors is particularly important in opioid toxicity because suppression of central respiratory drive can progressively reduce the rate and depth of ventilation. Kappa receptor activation has been associated with effects that include miosis, hallucinations, and dysphoria, while delta receptors contribute to pain modulation and may influence mood. Evidence also suggests that effective delta-mediated analgesia may depend partly on concurrent mu-receptor activity.[5][6]

Other opioid receptor systems contribute to the broader physiological effects of these substances. The nociceptin receptor has a role in regulating neuronal signaling and brain dopamine activity and may influence analgesia and anxiolysis. In contrast, the zeta receptor, also referred to as the opioid growth factor receptor, has been associated with regulation of cellular proliferation and tissue growth and appears to have a limited role in pain or emotional regulation.[7][8] The clinical manifestations of opioid toxicity become increasingly severe as receptor stimulation increases. At high exposure levels, excessive opioid-mediated suppression of respiratory centers can markedly reduce ventilatory drive. Progressive hypoventilation produces carbon dioxide retention and declining oxygenation, which can advance to apnea. Prolonged oxygen deprivation may cause cerebral hypoxic injury, cardiovascular collapse, and death. This mechanism explains why respiratory depression remains the principal life-threatening consequence of severe opioid toxicity. The risk becomes greater when opioids are combined with other substances that depress the central nervous system, particularly when the combined effects further impair consciousness, ventilation, and airway protection.[7][8]

Risk Factors

Risk factors for opioid misuse, opioid use disorder, and opioid overdose involve a combination of behavioral, psychological, clinical, pharmacological, and socioeconomic characteristics. A history of substance use represents an important risk factor because previous exposure to alcohol, illicit substances, or prescription medications associated with dependence may increase vulnerability to problematic opioid use. Current or previous substance abuse should therefore be incorporated into clinical

assessment before and during opioid therapy. Untreated psychiatric disorders may also increase susceptibility to opioid misuse, particularly when patients use medications to manage psychological distress, anxiety, depressive symptoms, or other unresolved mental health problems. Younger age has also been associated with increased vulnerability to problematic opioid use. In addition, uncertainty regarding the underlying cause of pain or behaviors suggesting pain exaggeration may complicate opioid prescribing and increase the risk of inappropriate or prolonged opioid exposure. A history of legal problems and previous psychological trauma can further contribute to vulnerability to opioid misuse. Psychological trauma may influence coping behaviors and may be associated with substance use as a means of managing distress. A strong desire or craving for prescription medications represents another clinically relevant indicator because persistent medication-seeking behavior may signal emerging problematic use. These factors should not be interpreted in isolation. A patient may have several risk characteristics simultaneously, and their presence does not establish that opioid misuse or addiction will occur. Instead, they should prompt appropriate assessment, monitoring, patient education, and consideration of strategies that reduce unnecessary exposure to opioids. The risk factors associated with opioid overdose differ in some respects and include both patient-related and treatment-related characteristics. Comorbid mental and medical disorders can increase vulnerability to adverse opioid effects, particularly when these conditions affect respiratory function, consciousness, medication metabolism, or adherence to treatment. A history of substance abuse, including alcohol use, represents an important overdose risk because combined exposure to substances that depress the central nervous system can increase sedation and respiratory suppression. Methadone use has also been associated with overdose risk because of its pharmacological characteristics and potential for accumulation. Higher opioid dosages increase the amount of opioid receptor stimulation and may therefore increase the likelihood of clinically significant respiratory depression. Concurrent benzodiazepine prescribing is another important concern because benzodiazepines can produce central nervous system depression that may compound opioid-induced sedation and respiratory impairment. Unemployment may represent a broader socioeconomic risk factor associated with overdose vulnerability, although its relationship with individual outcomes can be influenced by multiple underlying circumstances. Opioid-naive patients may also experience substantial effects at doses tolerated by individuals with established opioid tolerance. Sleep apnea represents an additional concern because pre-existing abnormalities in nocturnal breathing can increase vulnerability to opioid-associated respiratory depression.[9] Recognition of these risk factors supports structured nursing assessment, safer opioid prescribing, closer monitoring of high-risk patients, and early identification of clinical deterioration.

Assessment

Assessment of a patient with suspected opioid overdose requires systematic evaluation of consciousness, respiratory function, pupil size, airway protection, and other clinical manifestations associated with opioid exposure. Reduced responsiveness is a common finding and may range from mild drowsiness to profound central nervous system depression. The nurse should assess the patient's response to verbal and physical stimulation while simultaneously evaluating respiratory status because progressive respiratory depression represents a major cause of morbidity and mortality in opioid toxicity. Hypopnea, characterized by abnormally shallow or slow breathing, may occur as opioid-mediated suppression of the respiratory centers reduces ventilatory drive. Respiratory rate, respiratory depth, oxygen saturation, airway patency, and signs of inadequate ventilation should therefore be assessed repeatedly. Slow or indistinct speech may accompany central nervous system depression and can provide an additional clinical indication of opioid effects. Pupillary constriction, or miosis, is another characteristic finding associated with opioid exposure. However, its presence should be interpreted within the overall clinical context because constricted pupils may also occur in individuals who have developed opioid tolerance and are actively using opioids without experiencing the severe sedation or respiratory depression associated with overdose.[10] Consequently, miosis alone should not be considered sufficient evidence of opioid toxicity. The nurse should integrate pupillary findings with the patient's level of consciousness, respiratory pattern, medication history, and other clinical findings when determining the likelihood and severity of opioid toxicity. Gastrointestinal manifestations may also contribute to the assessment. Constipation is particularly common among individuals receiving opioids for prolonged periods and among older adults. Opioids reduce gastrointestinal motility, which can result in persistent constipation and other manifestations of gastrointestinal hypomotility. In some circumstances, however, opioid exposure may produce intestinal spasms, including the painful abdominal cramping sometimes described as "codeine cramps." Naloxone has been identified as a treatment option for opioid-induced bowel spasms.[10] The assessment should also include inspection of potential injection sites when intravenous or other parenteral opioid use is suspected. Small abrasion-like skin changes known as "track marks" may appear along superficial veins, most commonly on the extremities but occasionally on

the neck or other anatomical sites.[11] These findings should be documented objectively and considered alongside the patient's clinical presentation rather than interpreted independently. A comprehensive assessment therefore supports early recognition of opioid toxicity, identification of the likely exposure pattern, evaluation of complications, and timely initiation of appropriate management.

Evaluation

The evaluation of acute opioid poisoning is primarily clinical and should focus on the rapid identification of opioid-induced central nervous system and respiratory depression. The diagnosis should not be delayed while awaiting laboratory confirmation because opioid toxicity can progress rapidly from reduced respiratory effort to complete apnea, hypoxemia, cardiac arrest, and death. Initial evaluation should therefore prioritize the patient's airway, breathing, circulation, level of consciousness, and response to stimulation. Hypopnea is a particularly important finding because progressive reduction in respiratory rate and depth may substantially impair alveolar ventilation before complete respiratory arrest occurs. Continuous assessment of respiratory rate, respiratory effort, oxygen saturation, level of consciousness, and airway patency is essential throughout the evaluation and resuscitation process. Although naloxone is a central component of treatment for clinically significant opioid toxicity, restoration and maintenance of adequate ventilation remain the immediate priorities. Airway control and rescue ventilation should be initiated when spontaneous breathing is inadequate. Bag-valve-mask ventilation or another appropriate assisted-ventilation technique should be started promptly by the initial responder to restore oxygen delivery to vital organs while other members of the response team prepare and administer naloxone. This approach is particularly important because naloxone does not immediately correct hypoxemia that has already developed and should not replace effective ventilation. Basic Life Support and Advanced Cardiac Life Support principles should be incorporated into the resuscitation of patients with severe opioid poisoning, with interventions adapted to the patient's respiratory and cardiovascular status.

Adequate vascular access is also important because intravenous access permits administration of naloxone, fluids, and other medications when clinically indicated. An initial intravenous naloxone dose of approximately 0.4 to 0.8 mg has been described as capable of rapidly reversing neurological and cardiorespiratory manifestations of opioid toxicity.[12][13] However, the amount required can vary considerably according to the opioid involved, degree of exposure, patient characteristics, and response to treatment. Severe or unusual cases may require substantially greater cumulative doses, and published case reports have described exceptionally high naloxone requirements, including reports of doses reaching 100 mg during successful resuscitation from an individual overdose event.[3] Consequently, clinical response rather than reliance on a predetermined dose should guide ongoing management, with continued observation for recurrent respiratory depression when the duration of opioid effect exceeds that of naloxone. Laboratory investigation can support the broader clinical assessment but should not delay emergency treatment. Drug screening may be performed when additional information regarding substance exposure is required; however, routine toxicological screening has limited value for establishing a time-critical diagnosis of acute opioid poisoning because results may not become available rapidly enough to influence initial resuscitation.[14] The clinical presentation and response to appropriate opioid antagonism remain central to immediate evaluation. Toxicology testing may have greater utility in other contexts, including investigation of unexplained substance exposure or identification of occult opioid use during occupational screening. When disagreement exists regarding the accuracy of a drug-screening result, confirmatory analytical methods such as gas chromatography–mass spectrometry can provide more specific identification of substances present in the biological sample. In the United States, employment-related drug-testing programs may involve Medical Review Officers who assess and interpret drug-testing results within the established testing framework.[15][16][17]

Medical Management

Medical management of opioid use disorder has evolved from approaches centered primarily on abstinence and peer-supported recovery toward treatment models that incorporate pharmacotherapy, harm reduction, relapse prevention, and individualized clinical care. Traditional approaches commonly emphasized complete abstinence from opioids and other psychoactive substances, supported by counseling, peer mentorship, and recovery programs. Within some recovery settings, the concept of being drug-free has historically included avoidance of medications prescribed for therapeutic purposes. During the 2010s, harm-reduction principles became increasingly incorporated into addiction treatment, with greater recognition that treatment success should be evaluated through measurable clinical outcomes such as reduction in illicit opioid use, prevention of overdose, retention in treatment, and improvement in social and physical functioning. This shift expanded the role of evidence-based medications in the long-term management of opioid use disorder. Medication-based treatment includes methadone, buprenorphine, and naltrexone, which differ substantially in their pharmacological mechanisms and clinical applications. Methadone is a full mu-opioid receptor agonist and can reduce opioid withdrawal symptoms and cravings while maintaining opioid receptor activity under supervised treatment. Buprenorphine acts as a partial mu-opioid receptor agonist and has

antagonist activity at kappa receptors. Its pharmacological profile allows it to reduce withdrawal and craving while producing a ceiling effect on some opioid-related effects. Naltrexone differs from methadone and buprenorphine because it acts as an opioid receptor antagonist rather than an opioid agonist. Increasing clinical research has evaluated these treatment strategies in relation to treatment retention, relapse prevention, opioid abstinence, and other patient outcomes. Pharmacological treatment can therefore be integrated with behavioral interventions, counseling, psychosocial support, and ongoing clinical monitoring rather than being considered a substitute for comprehensive addiction care.



Figure 2: Medical management of opioid toxicity.

Extended-release or depot naltrexone provides another approach for patients seeking complete opioid avoidance. A depot naltrexone injection can provide opioid receptor blockade for approximately 30 days, during which opioid administration is expected to have substantially reduced or absent opioid effects because the medication occupies the relevant receptors.[18][19] However, this approach creates important clinical considerations. Because opioid receptor blockade can interfere with opioid analgesia, management of acute pain following trauma, surgery, or other medical emergencies can become more complex. Depot naltrexone is therefore unsuitable for some patients, including those with ongoing chronic pain requiring opioid analgesia. Careful assessment of pain status, opioid exposure, treatment goals, and the ability to maintain opioid abstinence is required before initiating antagonist-based treatment. Oral naltrexone is administered daily but presents an adherence challenge because patients who control their own dosing can discontinue treatment, limiting its effectiveness. Supervised administration by a family member or another responsible person has been proposed as a potential strategy for improving adherence, although such arrangements require appropriate clinical oversight and patient consent. Literature examining supervised medication administration in substance-use treatment has provided a basis for considering adherence-focused approaches in selected patients.[20][21][3]

Nursing Management

Nursing management of opioid toxicity requires rapid assessment, continuous monitoring, and prompt intervention to prevent respiratory failure and other life-threatening complications. The nurse should begin by assessing respiratory rate, depth, pattern, oxygenation, airway patency, and level of consciousness. Any evidence of respiratory distress, hypoventilation, cyanosis, or declining responsiveness should receive immediate attention. Oxygen therapy should be provided when clinically indicated, including when oxygen saturation falls below 89%, while recognizing that supplemental oxygen does not replace adequate ventilation when respiratory depression is present. The patient's ability to cough effectively should also be assessed because opioid-induced sedation can impair airway protection and secretion clearance. Lung auscultation should be performed to identify crackles, wheezing, diminished air entry, or other abnormal breath sounds that may indicate impaired ventilation or aspiration. Establishing intravenous access is important for rapid administration of medications and fluids. One or two large-bore intravenous lines may be established according to the patient's condition and institutional protocols. Opioid reversal medication, particularly naloxone, should be administered as prescribed or according to the applicable emergency protocol, with close observation of respiratory and neurological responses. Because reversal can be followed by recurrent respiratory depression, particularly when the opioid duration exceeds that of the antagonist, continued monitoring remains essential after administration. Cardiac monitoring should be initiated to identify clinically significant changes in heart rate or rhythm and to support continuous assessment during acute management. The nurse should reassess respiratory status, oxygenation, consciousness, and overall clinical response after opioid reversal. Any deterioration or inadequate response should be communicated immediately to the responsible physician or emergency response team. Documentation should include assessment findings, interventions, medication administration, patient response, and subsequent monitoring. Effective nursing management therefore combines early recognition of respiratory compromise with airway support, oxygenation, intravenous access, opioid reversal, cardiovascular monitoring, and continued reassessment.

Outcome Identification

Outcome identification in opioid management should focus on achieving effective pain control while minimizing the risks associated with opioid exposure, including respiratory depression, misuse, dependence, overdose, and opioid use disorder. Opioids may provide clinically meaningful analgesia for selected patients with chronic pain, but their use requires structured assessment, ongoing

monitoring, appropriate prescribing, and patient education. Nursing professionals have a central role in identifying and evaluating outcomes because they frequently assess pain intensity, functional status, medication use, adverse effects, adherence, and changes in the patient's clinical condition. The desired outcomes should extend beyond reduction in reported pain and should include maintenance of respiratory stability, preservation of functional capacity, appropriate medication use, recognition of adverse effects, and reduction of behaviors associated with unsafe opioid consumption. Patient education represents an important component of outcome identification and should address the therapeutic purpose of opioids, prescribed dosing, potential adverse effects, signs of excessive sedation and respiratory depression, risks associated with dose escalation, and the potential for tolerance, dependence, and addiction. Patients should also understand the importance of avoiding inappropriate combinations with substances or medications that can increase central nervous system depression. Nurses are well positioned to provide this education because they can reinforce information during medication administration, follow-up assessment, discharge planning, and subsequent clinical encounters. Education should also be evaluated rather than simply documented. The nurse can assess whether the patient understands the prescribed regimen, recognizes warning signs of toxicity, and knows when and how to seek emergency assistance.

Evidence indicates that opioid prescribing restrictions and patient education may contribute to reducing opioid exposure and may help address aspects of the opioid crisis in the short term. However, the long-term effects of these approaches on opioid dependence and addiction remain uncertain.[22][23][24] Consequently, outcome evaluation should not rely solely on reductions in opioid prescribing or medication consumption. Longer-term outcomes should include sustained improvement in pain-related function, appropriate medication use, avoidance of overdose, reduced problematic opioid use, and engagement with appropriate treatment when opioid use disorder develops. From a nursing perspective, successful outcomes should therefore be individualized and measurable. These may include stable respiratory function, absence of opioid toxicity, improved understanding of medication risks, adherence to the prescribed treatment plan, appropriate management of pain, and timely recognition of emerging dependence or misuse. Regular reassessment allows healthcare professionals to determine whether the therapeutic benefits of opioid treatment continue to outweigh potential harms and whether modification of the treatment plan, additional monitoring, or referral for specialized care is required. This approach supports patient safety while maintaining access to opioid analgesia when clinically appropriate.

Monitoring

Monitoring patients receiving opioid therapy requires a structured approach that addresses medication adherence, inappropriate use, diversion, and the development of opioid-related complications. Patients who demonstrate patterns of medication overuse or other behaviors associated with unsafe opioid consumption may require closer clinical follow-up and dispensing of smaller quantities at shorter intervals. This approach allows healthcare professionals to reassess pain control, functional status, adverse effects, medication use, and adherence before additional quantities are provided. More frequent contact can also create opportunities to identify changes in clinical status or emerging behaviors that may increase the risk of misuse or overdose. The purpose of intensified monitoring should remain patient safety and appropriate therapeutic use rather than punitive control of medication access. Pill counts can provide an additional method for assessing adherence to the agreed treatment regimen. When performed within an established clinical plan, pill counts may help identify medication use that differs from the prescribed schedule and may provide an opportunity to discuss barriers to adherence, accidental overuse, or possible diversion. Random urine toxicology testing can also contribute to monitoring in selected patients. Such testing may help identify the presence of prescribed medications or other substances that could increase the risk of toxicity. A written opioid treatment agreement can further clarify the responsibilities of both the patient and healthcare team, including expectations regarding medication use, monitoring, refill procedures, and circumstances requiring modification or discontinuation of opioid therapy. Prescription Monitoring Programs provide another important mechanism for reducing inappropriate prescribing and diversion. These systems allow authorized healthcare professionals to review prescription histories and identify patterns such as overlapping prescriptions, multiple prescribers, or repeated dispensing from different sources.[25] The information obtained through prescription monitoring should be interpreted alongside the patient's clinical history, pain condition, medication response, and other relevant findings. Monitoring is most effective when it combines clinical assessment, medication reconciliation, prescription data, appropriate toxicology testing, patient education, and regular reassessment. Such an integrated approach supports safer opioid prescribing while allowing healthcare professionals to identify problems early and intervene before medication misuse progresses to serious toxicity or overdose.

Coordination of Care

Coordination of care is an essential component of opioid safety because the management of opioid therapy frequently involves physicians, nurses, pharmacists, pain specialists, addiction professionals, emergency healthcare personnel, and

other members of the multidisciplinary team. The opioid crisis in the United States has resulted in substantial morbidity and mortality and has prompted the development of multiple clinical recommendations intended to reduce opioid-related harm. Healthcare professionals involved in prescribing, dispensing, administering, and monitoring opioids share responsibility for identifying risk factors, communicating concerns, and implementing appropriate safeguards. Effective coordination also requires clear documentation and communication between healthcare settings so that changes in opioid therapy, adverse events, and previous treatment responses are not overlooked. Clinical guidance has emphasized caution with high opioid doses and recommends avoiding unnecessarily high daily morphine-equivalent doses. Earlier guidance frequently identified dose ranges of approximately 90 to 200 mg morphine equivalents per day as levels requiring particular caution or avoidance. When converting patients from transdermal fentanyl to oral opioid therapy, dose reductions of approximately 25% to 50% have also been described to account for differences in opioid exposure and incomplete cross-tolerance. Opioid risk assessment tools, written treatment agreements, and urine drug testing have been recommended as components of strategies designed to reduce opioid-related risks.[26][27] However, these measures should complement rather than replace clinical judgment, individualized assessment, and ongoing communication with the patient. Pharmacists have an important role in multidisciplinary opioid safety because they review prescriptions before dispensing and can identify potentially concerning doses, drug interactions, duplication of therapy, and patterns of multiple prescribers. When a prescription raises clinical concerns, communication with the prescribing healthcare professional can facilitate reassessment before medication is dispensed. Pharmacists can also use available prescription databases to identify patterns that may warrant further evaluation. Where professional or regulatory requirements apply, pharmacists may have responsibilities for reporting suspected inappropriate prescribing or other concerns to the relevant authorities.[27][28] Effective coordination therefore depends on timely information exchange, shared responsibility, consistent documentation, and respect for the patient's clinical needs. A coordinated approach can reduce fragmented prescribing and improve continuity of care across primary care, hospital, pharmacy, pain management, addiction treatment, and emergency services.

Risk Management

Risk management in opioid therapy requires systematic identification of factors that increase the probability of misuse, respiratory depression, overdose, diversion, and other opioid-related complications. The substantial burden of opioid-related morbidity and mortality in the United States has led to the development of clinical recommendations intended to improve prescribing and monitoring practices. Physicians, nurses, pharmacists, and other healthcare professionals involved in opioid treatment have complementary responsibilities in reducing preventable harm. Earlier guidelines emphasized avoiding high opioid doses, with particular caution recommended when daily opioid exposure reached approximately 90 to 200 mg of morphine equivalents. Recommendations have also described reducing doses when converting between certain opioid formulations, including reductions of approximately 25% to 50% when initiating or switching from fentanyl patches to oral opioids. Risk assessment instruments, written treatment agreements, and urine drug testing have also been proposed as components of opioid risk management.[26][27] Risk management must also account for the underlying condition for which opioids are being considered. Patients with chronic pain should undergo appropriate evaluation before referral to opioid recovery or addiction services. Inadequate attention to pain control during such transitions can produce substantial distress and may contribute to other clinical complications. Opioid policy also demonstrates the importance of considering unintended consequences. During the 2000s and 2010s, efforts to restrict opioid prescribing and distribution in the United States were associated with changes in the availability of prescription opioids. The source text describes concerns that reducing street availability were accompanied by increased heroin use and did not produce an overall reduction in opioid-related deaths from all sources.[25] These observations highlight the need to evaluate interventions according to multiple outcomes rather than relying solely on prescription volume.

International experience has also contributed to discussions concerning alternative approaches to substance-use policy. Portugal experienced substantial problems involving drug dependence and overdose during the 2000s and early 2010s. Following regulatory changes that emphasized decriminalization and referral to publicly supported treatment, reductions in deaths among people with substance-use disorders were reported.[30] Such observations have contributed to international discussion regarding treatment access and public health approaches to substance use. Medication security also requires attention, particularly among older adults and people with disabilities who may be vulnerable to theft or inappropriate access to prescribed opioids.[25] Pharmacists can contribute to risk management by identifying high opioid doses, reviewing prescription histories, communicating concerns with prescribers, and following applicable professional and regulatory

procedures when inappropriate prescribing is suspected.[27][28] Overall, effective risk management requires individualized assessment, careful prescribing, monitoring, communication, medication security, and access to appropriate treatment for patients experiencing opioid-related problems [29].

Discharge Planning

Discharge planning after suspected or confirmed opioid overdose should focus on reducing the probability of recurrent toxicity and ensuring that patients and caregivers understand the measures required to prevent another overdose. Before discharge, healthcare professionals should reassess the patient's level of consciousness, respiratory status, oxygenation, cardiovascular stability, and response to treatment. Particular attention should be given to the possibility of recurrent respiratory depression when the opioid involved has a longer duration of action than the opioid antagonist used during emergency treatment. The discharge process should therefore include appropriate observation and clinical reassessment before the patient leaves the healthcare setting. Patients treated for suspected opioid overdose should receive education regarding the circumstances that may have contributed to the event and the measures required to reduce future risk. Naloxone should be provided when clinically appropriate, together with clear verbal and written instructions regarding its administration. Training should extend to family members, caregivers, or other individuals who may be present during a future overdose because an affected patient may be unable to administer the medication independently. Patients should understand that naloxone provides emergency opioid reversal and does not eliminate the need for emergency medical evaluation following suspected overdose. Education should also cover recognition of opioid toxicity, including marked sedation, reduced responsiveness, slow or abnormal breathing, and loss of consciousness.

Medication instructions should be reviewed before discharge. Patients should be advised not to exceed the prescribed opioid dose and should be encouraged to inform their healthcare provider about adverse effects, inadequate pain control, changes in medication use, or concerns regarding dependence. Particular emphasis should be placed on avoiding concurrent use of opioids with alcohol, benzodiazepines, or muscle relaxants unless specifically assessed and managed by the healthcare team because such combinations may increase central nervous system depression and respiratory risk.[31] Medication reconciliation should identify duplicate opioid prescriptions, other sedating medications, and changes in treatment that may have contributed to the overdose. Discharge planning should also address the underlying reason for opioid exposure. Patients with evidence of opioid misuse or opioid use disorder should be offered appropriate assessment and referral for addiction treatment when indicated. Those receiving opioids for chronic pain may require reassessment of analgesic goals and consideration of safer or multimodal pain-management strategies. Follow-up arrangements should be clear and should identify the responsible healthcare professional or service. Effective discharge planning therefore extends beyond providing medication instructions. It includes overdose-prevention education, naloxone access, assessment of ongoing opioid needs, review of interacting substances, communication with caregivers, and linkage to appropriate follow-up care. These measures can support continuity of care and reduce the risk of repeated opioid-related emergencies.

Conclusion:

Opioid toxicity requires an integrated approach that combines early clinical recognition, respiratory assessment, emergency intervention, nursing care, and long-term prevention. Respiratory depression and impaired consciousness remain central manifestations of severe toxicity, making airway protection, assisted ventilation, oxygenation, and appropriate naloxone administration critical components of acute management. Nursing professionals play a central role in continuous assessment, monitoring, medication administration, patient education, and recognition of recurrent toxicity. Risk assessment should consider opioid dose, previous substance use, concurrent medications, psychiatric and medical comorbidities, opioid tolerance, and respiratory disorders. Long-term management should extend beyond treatment of the acute overdose. Appropriate monitoring, prescription surveillance, medication reconciliation, pharmacist involvement, and multidisciplinary coordination can reduce opportunities for unsafe opioid use and diversion. Evidence-based pharmacotherapy, including methadone, buprenorphine, and naltrexone, provides additional options for patients with opioid use disorder. Discharge planning should include overdose education, appropriate naloxone access, medication safety, avoidance of hazardous drug combinations, and follow-up care. A coordinated nursing and health security approach can support safer opioid use, improve recognition of toxicity, and reduce preventable opioid-related morbidity and mortality.

References:

1. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013 Jun 01;87(11):766-72.
2. Lalic S, Jokanovic N, Ilomäki J, Gisev N, Lloyd B, Lubman DI, Bell JS. Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review. Res Social Adm Pharm. 2019 Aug;15(8):925-935.
3. Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018 Jan;9(1):63-88.
4. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von

Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010 Jan 19;152(2):85-92.
5. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol. 2000 Dec 27;410(2-3):249-268.
6. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005 Mar;57(1):1-26.
7. Caffrey CR, Lank PM. When good times go bad: managing 'legal high' complications in the emergency department. Open Access Emerg Med. 2018;10:9-23.
8. Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. Inj Epidemiol. 2017 Dec;4(1):24.
9. Huang X, Keyes KM, Li G. Increasing Prescription Opioid and Heroin Overdose Mortality in the United States, 1999-2014: An Age-Period-Cohort Analysis. Am J Public Health. 2018 Jan;108(1):131-136.
10. Massey J, Kilkenny M, Batdorf S, Sanders SK, Ellison D, Halpin J, Gladden RM, Bixler D, Haddy L, Gupta R. Opioid Overdose Outbreak - West Virginia, August 2016. MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):975-980.
11. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012 Jul;15(3 Suppl):ES67-92.
12. Borgundvaag B, McLeod S, Khuu W, Varner C, Tadrous M, Gomes T. Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study. CMAJ Open. 2018 Mar 01;6(1):E110-E117.
13. Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected? J Am Med Dir Assoc. 2005 Jul-Aug;6(4):265-9.
14. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999 Apr 06;130(7):584-90.
15. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007 Jul;61(7):1181-7.
16. Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998 Apr;5(4):293-9.
17. LoVecchio F, Pizon A, Riley B, Sami A, D'Incognito C. Onset of symptoms after methadone overdose. Am J Emerg Med. 2007 Jan;25(1):57-9.
18. Sporer KA, Firestone J, Isaacs SM. Out-of-hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med. 1996 Jul;3(7):660-7.
19. Owusu Obeng A, Hamadeh I, Smith M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy. 2017 Sep;37(9):1105-1121.
20. Ciejka M, Nguyen K, Bluth MH, Dubey E. Drug Toxicities of Common Analgesic Medications in the Emergency Department. Clin Lab Med. 2016 Dec;36(4):761-776.
21. Melanson SE, Baskin L, Magnani B, Kwong TC, Dizon A, Wu AH. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Arch Pathol Lab Med. 2010 May;134(5):735-9.
22. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009 Aug;10(11):1727-40.
23. Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984;10(2):249-66.
24. Wong F, Edwards CJ, Jarrell DH, Patanwala AE. Comparison of lower-dose versus higher-dose intravenous naloxone on time to recurrence of opioid toxicity in the emergency department. Clin Toxicol (Phila). 2019 Jan;57(1):19-24.
25. Pauly JB, Vartan CM, Brooks AT. Implementation and evaluation of an opioid overdose education and naloxone distribution (OEND) program at a Veterans Affairs Medical Center. Subst Abus. 2018;39(2):206-210.
26. Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016 Mar;81(3):428-36.
27. Saloner B, McGinty EE, Beletsky L, Bluthenthal R, Beyrer C, Botticelli M, Sherman SG. A Public Health Strategy for the Opioid Crisis. Public Health Rep. 2018 Nov/Dec;133(1_suppl):24S-34S.
28. Wiese B, Wilson-Poe AR. Emerging Evidence for Cannabis' Role in Opioid Use Disorder. Cannabis Cannabinoid Res. 2018;3(1):179-189.
29. Metfessel BA, Mentel MD, Phanel A, Dimartino MA, Allen M, Ho S. Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck. Pharmacoeconomics. 2019 Mar;37(3):419-433.
30. Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013 Jul;125(4):115-30.

Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-Effectiveness of Take-Home

Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom. Value Health. 2018 Apr;21(4):407-415.